Extrawell Pharmaceutical Holdings Limited (Extrawell Pharm) filed its monthly return for April 2026, highlighting a sizable increase in equity following a partial conversion of its Zero-Coupon Convertible Bonds due 2033.

Issued-Share Expansion • The company issued 350.00 million new ordinary shares during the month, lifting the total issued share count 13.73 % to 2.90 billion from 2.55 billion at March-end. • No treasury shares were held or cancelled, keeping the treasury balance at zero.

Driver of New Shares • HKD 224.46 million in principal amount of the convertible bonds was converted at HKD 0.6413 per share. • Outstanding bond principal declined to HKD 352.72 million, which can still be converted into up to 550.00 million additional shares.

Share Option Position • The 2022 Share Option Scheme shows 76.50 million options outstanding. • The scheme leaves headroom for a further 162.50 million shares, subject to future grants and exercises.

Capital Structure and Compliance • Authorised share capital remained unchanged at 20.00 billion shares (HKD 200.00 million par value). • The company confirmed compliance with the Hong Kong Stock Exchange’s 25 % minimum public-float requirement.

Looking Ahead The latest conversion materially lowers outstanding convertible debt while increasing share count, with a further 550.00 million shares potentially issuable from the remaining bonds and 162.50 million under the option scheme. Investors should monitor subsequent filings for additional conversions or option exercises that could further affect dilution and capital structure.